An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

NCT06254482 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Huntington Disease

Interventions

DRUG: Votoplam

Sponsor

Novartis Pharmaceuticals